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BRIEF COMMUNICATIONS: TECHNICALBrief CommunicationsCongenital type II atrial septal defect (ASD) is associated
with precapillary pulmonary hypertension (PAH) in roughly
10% of cases.1 Principally, closure of the shunt lesion is
recommended, and large ASDs must be repaired in early
childhood to prevent Eisenmenger’s syndrome. Once severe
pulmonary hypertension or Eisenmenger’s syndrome has
developed, ASD closure is problematic due the increased
risk of right ventricular failure and pulmonary hypertensive
crisis.2 At this stage, heart–lung transplantation is the only
surgical option. Nonsurgical strategies include supplemental
oxygen, digitalis, anticoagulation, and vasodilator treat-
ments.
In contrast to the traditional rule of inoperability of an
ASD with severe pulmonary hypertension, single case re-
ports have demonstrated that surgical correction of an
ASD is feasible but requires longtime pre- and postoperative
treatment with vasodilators.3-5
Endothelin receptor antagonists are a new class of vasoac-
tive substances, some of which (eg, bosentan) are orally
active. Bosentan has been shown to lower pulmonary artery
pressure (PAP) and to induce reverse remodeling of the
pulmonary arteries.
We report the case of a patient with type II ASD and se-
vere pulmonary hypertension. Successful surgical closure
of the ASD was possible with near-normalized PAPs after
10 months of ‘‘conditioning’’ medication with bosentan.
CLINICAL SUMMARY
A 71-year-old woman was admitted to hospital because of
exercise intolerance and cough. She presented in World
Health Organization functional class IV and was given per-
manent oxygen. Pneumonia was diagnosed and an antibiotic
regimen was started. Electrocardiography showed a right
bundle branch block with left axis deviation of 130.
Routine echocardiography revealed severe pulmonary hy-
pertension with a systolic PAP of 89 mm Hg and a large
type II ASD with a bidirectional shunt. The defect size
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diac catheterization confirmed the diagnosis of severe PAH
with a pulmonary vascular resistance over 400dynes $ s $
cm5, which is the cutoff for shunt closures at our institution,
and a nitric oxide nonresponder status6 (Table 1). Surgical
repair of the type II ASD was deemed impossible because
of the degree of PAH with a mean PAP of 54, high B-type
natriuretic peptide, and the patient’s severe physical limita-
tion. Bosentan therapy to condition the patient toward a later
ASD closure was found to be an option by an interdisciplin-
ary consent. Bosentan was started at a dosage of 125 mg/d (2
3 62.5 mg twice a day) and was increased to 250 mg/d after
1 month. Laboratory parameters were controlled monthly,
and no significant elevation of liver enzymes occurred.
Ten months after initiation of bosentan, repeat cardiac cath-
eterization revealed significantly reduced pulmonary pres-
sures (Table 1), stimulating a surgical closure of the type
II ASD with a Dacron patch. In addition, the patient’s tricus-
pid valve insufficiency was repaired utilizing an Edwards
Lifesience (Irvine, Calif) MC3 32-mm ring. The patient
was extubated on the first postoperative day; norepinephrine
and dobutamine given for cardiac support were stopped 2
days later. During the further postoperative course, recurrent
right-sided pleural effusion and a sudden pericardial tampo-
nade had to be tapped. The patient was discharged from the
hospital on postoperative day 28 under bosentan treatment
(250 mg/d). Eight months thereafter, the patient was in
good clinical condition with mild pulmonary hypertension.
DISCUSSION
In this case report, we describe significant hemodynamic
improvement under bosentan therapy, allowing surgical
closure of a type II ASD 10 months after bosentan induction,
with good clinical outcome 8 months postoperatively.
Treatment options for elderly patients suffering from pul-
monary hypertension are limited. Medical treatment is the
standard therapeutic option, as surgical closure of the shunt
is associated with an increased postoperative mortality.2 The
main obstacle for surgical treatment is right ventricular
dysfunction/failure in the presence of severe pulmonary
hypertension after the surgical intervention. However,
several recent case reports have demonstrated that postoper-
ative reduction of PAP significantly reduces the risk of right
heart failure, making surgical closure a possible treatment
option.3,4
Recently, Frost et al5 reported a vasodilatative ‘‘condi-
tioning’’ therapy in a patient with Eisenmenger’s syndromergery c March 2009
Brief CommunicationsTABLE 1. Time course of clinical and hemodynamic parameters
Before bosentan initiation
Before ASD repair
8 months after ASD
repairParameter Baseline NO (20 ppm)
mLAP (mm Hg) 17 17 11 13
mRAP (mm Hg) 16 16 10 7
mPAP (mm Hg) 54 42 30 35
Pulmonary/systemic flow (L/min) 9.5/3.5 14.0/4.3 7.4/3.3 5.2/5.2
Arterial saturation (%) 91 95 88 95
Pulmonary arterial saturation (%) 75 84.5 77.7 62.0
Total pulmonary resistance (dynes $ s $ cm5) 460 240 325 538
B-type natriuretic peptide (pg/mL) 4675 1104 420
6-min walking distance (m) 152.2 241.0 247.0
ASD, Atrial septal defect; NO, nitric oxide; mLAP, mean left atrial pressure; mRAP, mean right atrial pressure; ND, not done; mPAP, mean pulmonary arterial pressure.that was initially considered inoperable. The type II ASD
in this case could be closed after 4 years of epoprostenol
therapy. Eight years after surgical intervention, the pa-
tient is clinically stable with near-normal pulmonary
pressures.5
We now present a similar case treated with bosentan.
Bosentan has several advantages compared to epoprostenol.
Because it is an oral drug, there are no complications related
to intravenous delivery systems, which are common under
prostaglandin therapy. Furthermore, adverse side effects of
epoprostenol including headache, diarrhea, and rash are
avoided. By contrast, the side effect profile of oral bosentan
includes elevated liver enzymes in 7% of cases. Fortunately,
no clinically relevant increases of transaminases occurred in
our patient during 16 months of follow-up.
In the described case, bosentan was continued because of
the 8-month hemodynamic data together with the assump-
tion that a pulmonary vascular disease was present. As the
clinical outcome in this elderly patient was excellent, further
invasive diagnostic procedures reevaluating bosentan ther-
apy were abandoned.The Journal of Thoracic and CWe conclude that bosentan treatment of a patient with
type II ASD and severe pulmonary hypertension results in
an amelioration of pulmonary hypertension that may allow
surgical correction according to standard operating proce-
dures of pulmonary hypertension units.
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